NYSE : HAE
Haemonetics Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 119.65 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.44B |
| Enterprise Value | 6.39B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.50M |
| Shares Outstanding | 45.50M |
| Shares Change (YoY) | -6.48% |
| Shares Change (QoQ) | -1.12% |
| Owned by Insiders (%) | 1.30% |
| Owned by Institutions (%) | 109.65% |
| Float | 44.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 58.11 |
| Forward PE | 21.72 |
| PS Ratio | 4.03 |
| Forward PS | 3.79 |
| PB Ratio | 6.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.69 |
| P/OCF Ratio | 16.59 |
| PEG Ratio | 2.01 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 66.40 |
| EV / Sales | 4.73 |
| EV / EBITDA | 17.82 |
| EV / EBIT | 25.09 |
| EV / FCF | 21.95 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.08 |
| Quick Ratio | 1.67 |
| Debt / Equity | 1.40 |
| Debt / EBITDA | 3.18 |
| Debt / FCF | 4.03 |
| Interest Coverage | 9.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 11.20% |
| Return on Assets (ROA) | 6.60% |
| Return on Invested Capital (ROIC) | 10.42% |
| Return on Capital Employed (ROCE) | 12.12% |
| Weighted Average Cost of Capital (WACC) | 6.55% |
| Revenue Per Employee | $449,323 |
| Profits Per Employee | $32,000 |
| Employee Count | 3,009 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.65 |
Taxes
| Measure | Value |
|---|
| Income Tax | 34.15M |
| Effective Tax Rate | 26.18% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +142.01% |
| 50-Day Moving Average | 109.98 |
| 200-Day Moving Average | 78.64 |
| Relative Strength Index (RSI) | 63.27 |
| Average Volume (20 Days) | 750,494 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.43M |
| Short Previous Month | 3.42M |
| Short % of Shares Out | 7.53% |
| Short % of Float | 7.64% |
| Short Ratio (days to cover) | 4.81 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.35B |
| Gross Profit | 802.16M |
| Operating Income | 254.82M |
| Pretax Income | 130.44M |
| Net Income | 96.29M |
| EBITDA | 358.79M |
| EBIT | 254.82M |
| Earnings Per Share (EPS) | $2.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 224.52M |
| Total Debt | 1.17B |
| Net Cash | -949.64M |
| Net Cash Per Share | -$20.87 |
| Equity (Book Value) | 837.10M |
| Book Value Per Share | 18.41 |
| Working Capital | 547.60M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 328.15M |
| Capital Expenditures | -36.93M |
| Depreciation & Amortization | 103.97M |
| Net Borrowing | -56.25M |
| Free Cash Flow | 291.22M |
| FCF Per Share | $6.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | 59.33% |
| Operating Margin | 18.85% |
| Pretax Margin | 9.65% |
| Profit Margin | 7.12% |
| EBITDA Margin | 26.54% |
| EBIT Margin | 18.85% |
| FCF Margin | 21.54% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 6.48% |
| Shareholder Yield | 6.48% |
| Earnings Yield | 1.72% |
| FCF Yield | 5.35% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $124.50 |
| Price Target Difference | 4.05% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 6.23% |
| EPS Growth Forecast (3Y) | 9.34% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.58 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |